Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Edwards Lifesciences, TAVR and Stifel
Edwards Lifesciences Is Poised For Solid Growth In 2025—Analyst Highlights TAVR Growth, Margin Expansion
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025.
Edwards Lifesciences upped to Buy at Stifel on TAVR growth
Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve replacement (TAVR).
Edwards Lifesciences upgraded to Buy from Hold at Stifel
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR,
Stifel raises Edwards Lifesciences stock to buy, target to $90
Stifel analysts upgraded Edwards Lifesciences (NYSE:EW) stock from Hold to Buy, citing potential growth acceleration in the Transcatheter Aortic Valve Replacement (TAVR) market. The firm also increased its price target on the company from $75.
Healio
23h
CABG plus surgical AVR may suit certain older patients with aortic stenosis, CAD
CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...
GlobalData on MSN
4d
Caranx Medical submits AI TAVI-TAVR guide software to FDA
TAVIPILOT Soft is said to be a ‘world-first’ provision for real-time surgical guidance during TAVI and TAVR procedures.
The Valdosta Daily Times
11d
SGMC Health performs its first alternative access Transcatheter Aortic Valve Replacement
SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...
MassDevice
8d
Analysts expect JenaValve TAVR approval for aortic regurgitation in 2025
GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...
11d
无症状重度主动脉瓣狭窄继续随访还是提早TAVR?EARLY TAVR研究给出了明确答案
该公众号是个人的读书笔记,结论仅供参考,转发需特别谨慎,纠错请留言。 对于无症状的重度主动脉瓣狭窄且左心室射血分数保留的患者,目前的指南建议每 6 至 12 个月进行一次常规临床随访。也就是说,目前还不推荐这些患者可以常规提前进行经导管主动脉瓣置换术 (TAVR) 。 EARLY TAVR研究探索了这一临床问题,研究在美国和加拿大的 75 个中心,以 1:1 的比例随机分配了901例无症状严重主动 ...
Medical Design and Outsourcing
6d
What is minimally invasive medtech? Device experts offer their thoughts
Minimally invasive medtech can include surgical robots, miniaturized implants and therapeutic catheters — but it depends who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Edwards Lifesciences
Stifel
Army Reserve
Feedback